Major impact of hormonal therapy in localized prostate cancer—death can already be an exception

Labrie, Fernand; Cusan, Lionel; Luu‐The, Van; Candas, Bernard; Bélanger, Alain; Labrie, Claude

doi:10.1016/j.jsbmb.2004.10.011

Cited by 18 publications

(19 citation statements)

References 95 publications

(188 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar positive results have been reported in Canada and in Europe [34][35][36] . Labrie et al [34,35] in Canada have reported the results of a series of studies which have demonstrated a major reduction in deaths from prostate cancer ranging from 31 to 87% at 5 years of follow-up in patients with localized or locally advanced prostate cancer.…”

Section: Trends In the Use Of Hormonal Therapy For Localized And Locasupporting

confidence: 90%

“…Labrie et al [34,35] in Canada have reported the results of a series of studies which have demonstrated a major reduction in deaths from prostate cancer ranging from 31 to 87% at 5 years of follow-up in patients with localized or locally advanced prostate cancer. Notably, they report that CAB can lead to a 90% longterm control or probable cure of prostate cancer in this setting.…”

Section: Trends In the Use Of Hormonal Therapy For Localized And Locamentioning

confidence: 99%

See 1 more Smart Citation

Future Prospects for Luteinizing Hormone-Releasing Hormone Analogues in Prostate Cancer Treatment

Akaza

2010

Pharmacology

View full text Add to dashboard Cite

Luteinizing hormone-releasing hormone (LHRH) analogues play a pivotal role in hormonal therapy regimens for the treatment of prostate cancer. Hormonal therapy has traditionally been used as a palliative treatment for patients with advanced disease, and international treatment guidelines do not recommend its use as a first-line therapy at earlier disease stages. However, there appears to be a gap between international guideline recommendations and actual clinical practice regarding the use of primary androgen deprivation therapy (PADT) for prostate cancer therapy. Despite limited evidence to date for the impact on clinical outcomes, the use of PADT in patients with localized or locally advanced prostate cancer has increased in many countries, most notably Japan. Clinical evidence is now accumulating to confirm the valuable role of PADT, both as monotherapy but particularly when used as part of a maximal androgen blockade regimen, on the long-term control of both localized and locally advanced disease, and importantly on survival outcomes in these patients.

show abstract

Section: Trends In the Use Of Hormonal Therapy For Localized And Locasupporting

confidence: 90%

Section: Trends In the Use Of Hormonal Therapy For Localized And Locamentioning

confidence: 99%

Future Prospects for Luteinizing Hormone-Releasing Hormone Analogues in Prostate Cancer Treatment

Akaza

2010

Pharmacology

View full text Add to dashboard Cite

show abstract

“…Research by Labrie et al (2004) suggests that the intracrine production of biologically active androgens within the prostate may make a similar contribution to levels obtained from the uptake of circulatory testosterone. Immunohistochemistry studies have revealed that STS is present in 85% of malignant specimens of prostate cancer tissue but absent in the non-neoplastic peripheral zones (Nakamura et al 2006).…”

Section: Androgen Metabolismmentioning

confidence: 98%

Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers

Purohit¹,

Foster²

2011

Journal of Endocrinology

116

View full text Add to dashboard Cite

Estrogens and androgens are instrumental in the maturation of many hormone-dependent cancers. Consequently, the enzymes involved in their synthesis are cancer therapy targets. One such enzyme, steroid sulfatase (STS), hydrolyses estrone sulfate, and dehydroepiandrosterone sulfate to estrone and dehydroepiandrosterone respectively. These are the precursors to the formation of biologically active estradiol and androstenediol. This review focuses on three aspects of STS inhibitors: 1) chemical development, 2) biological activity, and 3) clinical trials. The aim is to discuss the importance of estrogens and androgens in many cancers, the developmental history of STS inhibitor synthesis, the potency of these compounds in vitro and in vivo and where we currently stand in regards to clinical trials for these drugs. STS inhibitors are likely to play an important future role in the treatment of hormone-dependent cancers. Novel in vivo models have been developed that allow pre-clinical testing of inhibitors and the identification of lead clinical candidates. Phase I/II clinical trials in postmenopausal women with breast cancer have been completed and other trials in patients with hormone-dependent prostate and endometrial cancer are currently active. Potent STS inhibitors should become therapeutically valuable in hormone-dependent cancers and other non-oncological conditions.

show abstract

“…The intraprostatic conversion of adrenally derived androgens is thought to be the most significant source of residual tissue androgens following testicular androgen ablation [1,46]. In addition, recent studies have identified alterations in several key enzymes involved in sterol biosynthesis and androgen metabolism in prostate tumor samples from castrate patients, suggesting that intracrine modulation of androgen metabolic pathways or de novo androgen synthetic pathways may also contribute to maintaining tissue androgen activity [44•,47,48,49••].…”

Section: Evidence For Suboptimal Suppression Of the Tumoral Androgen mentioning

confidence: 99%

“…Although initially highly effective in hormone-naïve patients, ADT is uniformly marked by progression to recurrent, castration-resistant disease over a period of 18 to 20 months following initiation of therapy in patients with metastatic disease, with an ensuing median survival of 1 to 2 years. Combined androgen blockade, intended to block the activity of residual adrenally derived androgens by combining testicular androgen suppression using a gonadotropin-releasing hormone analogue (GnRHa) with an androgen receptor antagonist, has yielded only limited improvement in overall survival compared with testicular androgen suppression alone [1,2]. Intermittent androgen suppression has been studied in an effort to delay progression to castration-resistant disease and to decrease the side effects of continuous therapy; the results of several ongoing randomized trials are awaited.…”

Section: Introductionmentioning

confidence: 99%

The basic biochemistry and molecular events of hormone therapy

Mostaghel

Montgomery²,

Lin³

2008

Curr prostate rep

View full text Add to dashboard Cite

Data regarding the molecular response of prostate cancer to hormone therapy continue to emerge, identifying a complex network of autocrine and paracrine signaling events mediating the tumor response to androgen suppression. Emerging data provide insight into cellular pathways important in the apoptotic response to therapy, including the transforming growth factor-, insulin-like growth factor-1, and vascular endothelial growth factor signaling axes. They also reveal mechanisms of direct antitumor cytotoxicity mediated by various hormonal agents and highlight the importance of developing antiandrogens capable of irreversibly inhibiting the androgen receptor. Accumulated data emphasize the presence of residual androgens and persistent activation of androgen receptor signaling in advanced prostate tumors despite castration. These factors suggest that a multitargeted treatment approach designed to ablate all contributions to the androgen receptor signaling axis within the prostate tumor microenvironment will be required in order for hormonal therapy to achieve optimal antitumor efficacy.

show abstract

Major impact of hormonal therapy in localized prostate cancer—death can already be an exception

Cited by 18 publications

References 95 publications

Future Prospects for Luteinizing Hormone-Releasing Hormone Analogues in Prostate Cancer Treatment

Future Prospects for Luteinizing Hormone-Releasing Hormone Analogues in Prostate Cancer Treatment

Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers

The basic biochemistry and molecular events of hormone therapy

Contact Info

Product

Resources

About